Emerging technologies in autoantibody testing for rheumatic diseases

Nancy J. Olsen, May Y. Choi, Marvin J. Fritzler

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Testing for the presence of antinuclear antibodies (ANAs) is a key step in the diagnosis of systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARD). The standard slide-based indirect immunofluorescence (IIF) test is widely used, but is limited by a relative lack of specificity for SLE and not all SARD-ANAs are detected. Alternative immunoassays that might offer enhanced diagnostic and prognostic information have evolved, and some of these have entered clinical practice. This review summarizes the current state of ANA testing and multiplex techniques for detecting other autoantibodies, the possibility of point-of-care testing, and approaches for applications in early disease stages.

Original languageEnglish (US)
Article number172
JournalArthritis Research and Therapy
Volume19
Issue number1
DOIs
StatePublished - Jul 24 2017

Fingerprint

Antinuclear Antibodies
Rheumatic Diseases
Autoantibodies
Technology
Systemic Lupus Erythematosus
Autoimmune Diseases
Indirect Fluorescent Antibody Technique
Immunoassay

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

@article{997f635ac5d64b5c8e7d2f36101ec2cb,
title = "Emerging technologies in autoantibody testing for rheumatic diseases",
abstract = "Testing for the presence of antinuclear antibodies (ANAs) is a key step in the diagnosis of systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARD). The standard slide-based indirect immunofluorescence (IIF) test is widely used, but is limited by a relative lack of specificity for SLE and not all SARD-ANAs are detected. Alternative immunoassays that might offer enhanced diagnostic and prognostic information have evolved, and some of these have entered clinical practice. This review summarizes the current state of ANA testing and multiplex techniques for detecting other autoantibodies, the possibility of point-of-care testing, and approaches for applications in early disease stages.",
author = "Olsen, {Nancy J.} and Choi, {May Y.} and Fritzler, {Marvin J.}",
year = "2017",
month = "7",
day = "24",
doi = "10.1186/s13075-017-1380-3",
language = "English (US)",
volume = "19",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

Emerging technologies in autoantibody testing for rheumatic diseases. / Olsen, Nancy J.; Choi, May Y.; Fritzler, Marvin J.

In: Arthritis Research and Therapy, Vol. 19, No. 1, 172, 24.07.2017.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Emerging technologies in autoantibody testing for rheumatic diseases

AU - Olsen, Nancy J.

AU - Choi, May Y.

AU - Fritzler, Marvin J.

PY - 2017/7/24

Y1 - 2017/7/24

N2 - Testing for the presence of antinuclear antibodies (ANAs) is a key step in the diagnosis of systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARD). The standard slide-based indirect immunofluorescence (IIF) test is widely used, but is limited by a relative lack of specificity for SLE and not all SARD-ANAs are detected. Alternative immunoassays that might offer enhanced diagnostic and prognostic information have evolved, and some of these have entered clinical practice. This review summarizes the current state of ANA testing and multiplex techniques for detecting other autoantibodies, the possibility of point-of-care testing, and approaches for applications in early disease stages.

AB - Testing for the presence of antinuclear antibodies (ANAs) is a key step in the diagnosis of systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARD). The standard slide-based indirect immunofluorescence (IIF) test is widely used, but is limited by a relative lack of specificity for SLE and not all SARD-ANAs are detected. Alternative immunoassays that might offer enhanced diagnostic and prognostic information have evolved, and some of these have entered clinical practice. This review summarizes the current state of ANA testing and multiplex techniques for detecting other autoantibodies, the possibility of point-of-care testing, and approaches for applications in early disease stages.

UR - http://www.scopus.com/inward/record.url?scp=85025430107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025430107&partnerID=8YFLogxK

U2 - 10.1186/s13075-017-1380-3

DO - 10.1186/s13075-017-1380-3

M3 - Review article

C2 - 28738887

AN - SCOPUS:85025430107

VL - 19

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

M1 - 172

ER -